高脂血症用薬フェノフィブラートの空腹時血糖値への影響

概要

論文の詳細を見る
The effect of anti-hyperlipidemic agent fenofibrate on the fasting plasma glucose (FPG) Ievels was investigated. Twenty-one hyperlipidemia patients received fenofibrate therapy. In non-diabetic patients and type II diabetes mellitus patients who did not receive sulfonylurea therapy, the FPG Ievels after the administration of fenofibrate did not change significantly before therapy. However, in type II diabetes mellitus patients receiving sulfonylurea therapy, the FPG Ievels significantly decreased from 206±13.6mg/dL to 170±16.1mg/dL, 181±21.3mg/dL, and 163±15.2mg/dL in 4, 8 and 12 weeks, respectively. The effect of age on the FPG Ievels after fenofibrate therapy was not demonstrated in adult patients, however, those levels in patients over the age of 65 decreased from 153±26.2mg/dL to 129±20.8mg/dL in 12 weeks. Those results showed that the FPG Ievels decreased after a combination of fenofibrate and sulfonylurea in type II diabetes mellitus patients, and the decrease in the FPG Ievels after fenofibrate therapy was found to be affected by aging.
日本医療薬学会の論文
2001-12-10